Anthera Pharmaceuticals (ANTH)
Anthera Pharmaceuticals Cash and ST Investments: 44.03M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
ANTH Cash and ST Investments Rankings
| Overall | 37th percentile | 2718 of 4365 |
| Sector | 45th percentile | 275 of 504 in Healthcare |
| Industry | 31st percentile | 17 of 25 in Drug Manufacturers - Major |
ANTH Cash and ST Investments Range, Past 5 Years
| Minimum | 3.803M | Dec 2009 |
| Maximum | 112.10M | Jun 2011 |
| Average | 64.33M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these ANTH related companies
ANTH News
Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); All Eyes on June Phase 2 Data
May 07, 9:07AM Street Insider
May 07, 9:07AM Street Insider
Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
May 03, 5:00PM PR Newswire
May 03, 5:00PM PR Newswire
Anthera Announces First Quarter 2012 Financial Report and Conference Call
Apr 27, 12:00PM PR Newswire
Apr 27, 12:00PM PR Newswire
Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Apr 25, 2:30PM Benzinga
Apr 25, 2:30PM Benzinga
Shorted $ANTH @ 2.63. Currently 2.41--looking for 2.33 with a stop at 2.50.
about 38 days ago by 228investing
about 38 days ago by 228investing
$ANTH buyers today...Been holding for a few weeks now for LUPUS data due mid year...This could be a flyer
about 39 days ago by holiday613
about 39 days ago by holiday613
Anthera Pharmaceuticals to Present at the BioCentury Future Leaders Conference
Apr 17, 3:00PM PR Newswire
Apr 17, 3:00PM PR Newswire
Love the accumulation in $ANTH last few days..positive divergence from overall down mkt..Me thinks the bottom is in
about 52 days ago by holiday613
about 52 days ago by holiday613
$ANTH basing very nicely here...Lupus data due mid year..Looks like an easy double from here imo
about 52 days ago by holiday613
about 52 days ago by holiday613
$ANTH .Started accumulating a position today..The cheapest play on Lupus that i can see .
about 55 days ago by holiday613
about 55 days ago by holiday613
$ANTH filed latest Proxy Statement with the SEC (Form DEF 14A) http://stks.co/38sq
about 59 days ago by MarketBrief
about 59 days ago by MarketBrief
Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Expectations for June Phase 2 PEARL Trial
Mar 29, 8:40AM Street Insider
Mar 29, 8:40AM Street Insider
Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); Looking Ahead to Other B-Mod Programs
Mar 19, 8:51AM Street Insider
Mar 19, 8:51AM Street Insider
Anthera Pharmaceuticals (ANTH) Cuts 45% of Workforce After Termination of VISTA-16 Study
Mar 15, 5:05PM Street Insider
Mar 15, 5:05PM Street Insider
Anthera Pharma (ANTH) Crushed on Plans to Stop VISTA-16 Trial Due to Lack of Efficacy
Mar 12, 10:52AM Street Insider
Mar 12, 10:52AM Street Insider
Canaccord Genuity Maintains a 'Buy' on Anthera Pharma (ANTH); Hard Stop to Varespledib/A001 Development
Mar 12, 8:36AM Street Insider
Mar 12, 8:36AM Street Insider
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ANTH | 1.85 | -0.06 | -3.14% | 75.83M |
| ANSS | 62.09 | +0.40 | +0.65% | 5.761B |
| ANR | 11.17 | +0.00 | +0.00% | 2.458B |
| ANO | 0.298 | +0.00 | +0.00% | 60.16M |
| AIV | 26.71 | -0.04 | -0.15% | 3.237B |
| AIT | 37.16 | -0.13 | -0.35% | 1.561B |
| AIS | 2.89 | +0.02 | +0.70% | 299.69M |
| AIRT | 9.250 | +0.17 | +1.87% | 22.66M |
| AIRM | 91.97 | -0.12 | -0.13% | 1.159B |
| AIR | 12.48 | -0.29 | -2.27% | 502.69M |
